A case of gastric cancer with liver metastases had a complete response with cisplatin and capecitabine as third-line chemotherapy

Teker F., Canbaz F., Kemal Y., Yucel I.

Journal of Cancer Research and Therapeutics, vol.11, no.4, pp.1079-1081, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.4103/0973-1482.150348
  • Journal Name: Journal of Cancer Research and Therapeutics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1079-1081
  • Keywords: Capecitabine, chemotherapy, cisplatin, gastric cancer, third line, treatment
  • Ondokuz Mayıs University Affiliated: Yes


Advanced gastric cancer has a poor prognosis, and only chemotherapy improves survival. Further chemotherapy after progression is controversial. Eastern Cooperative Oncology Group performance status is an important indicator for new chemotherapy decision. Complete response (CR) after recurrent disease is very rare, but could occur in some cases with chemotherapy. The 68-year-old male received chemotherapy for metastatic gastric adenocarcinoma. He received epirubicin, cisplatin and fluorouracil in the first line, capecitabine in the second line and cisplatin-capecitabine in the third line. CR was observed after third-line chemotherapy with four courses. Mediastinal and abdominal metastases were completely resolved. We decided to report this patient because it is very unusual to achieve CR in a patient in whom the best supportive care might be reasonable.